A new inhaled treatment for chronic obstructive pulmonary disease (COPD)
Official title: An Inhaled Microbiome-Targeted Biotherapeutic for Treatment of COPD
Funded at Alveolus Bio, INC. · NIH-11041173 · Data updated 2026-11-12
This study is testing a new inhaled treatment called RB1000 to help people with COPD by reducing lung inflammation and improving breathing, while also keeping an eye on how it affects their overall health.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Alveolus Bio, INC. NIH-funded |
| Lab location | 1 site (Birmingham, United States) |
| Project start | March 1, 2023 |
| Project end | February 28, 2026 |
| Funding year | 2025 |
| Award (this year) | $992,385 |
| NIH project number | 5R44HL164156-04 |
| Project ID | NIH-11041173 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with chronic obstructive pulmonary disease (COPD), particularly those experiencing frequent exacerbations.
✕Less likely to help
Patients with mild or early-stage COPD who do not experience significant symptoms may not benefit from this research.
What this research studies
This research focuses on developing a novel inhaled biotherapeutic called RB1000, designed to target inflammation in patients with chronic obstructive pulmonary disease (COPD). The treatment aims to address the underlying issues caused by an altered lung microbiome, which contributes to disease progression and acute exacerbations. By using a spray-dried powder formulation, the therapy seeks to improve lung function and reduce the frequency of symptom flare-ups. Patients will be monitored for changes in their condition and overall health status as part of the treatment process.
Why it matters
Potential benefit: If successful, this research could lead to a more effective treatment option for COPD patients, potentially reducing symptoms and improving quality of life.
How similar studies have gone: While the approach of targeting the lung microbiome in COPD is relatively novel, previous studies have shown promise in using microbiome modulation for other chronic inflammatory conditions.
Where this research is happening
-
Alveolus Bio, INC.
Birmingham, United States Active
Researchers
- Principal investigator: Nicola, Teodora — Alveolus Bio, INC.
- Study coordinator: Nicola, Teodora
Related research
Other NIH-funded projects on the same topics.
-
Omalizumab for COPD patients with allergen sensitization and exposure
A multicenter trial will test whether adding omalizumab helps people with COPD who are allergic to common indoor allergens and are exposed to them.
-
Clinical CT Imaging to identify and subtype pulmonary hypertension in COPD
A new CT imaging approach aims to help doctors detect and classify pulmonary hypertension in people with COPD.
-
Next-Generation Wearable AI for Precision COPD Risk and Care
A patient-centered project uses a smart wearable and AI to predict COPD flare-ups and support doctors in making better care decisions.
-
Ethics-aware Multimodal AI for COPD prevention, diagnosis, and treatment
A broad AI model uses diverse health data to help predict and manage COPD in people, with an emphasis on ethics and fairness.
-
Easier, local pulmonary rehab and social support for people with COPD in low-resource clinics
This project compares a 10-week community pulmonary rehabilitation program alone, the same program plus help with social needs, and usual care for people with moderate-to-severe COPD to see which helps people stick with rehab and feel better.
-
Improving COPD outcomes with real-world data
A doctor-scientist at a major university is using real-world information from COPD patients to understand which treatments work best, how safe they are, and whether people stick to their inhaler plans.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.